AFMK

Details:

AFMK is an antioxidant metabolite of melatonin, which can alleviate oxidative damage to DNA, protein, and lipids in mice caused by X-rays. AFMK is a poor scavenger. The pKa of AFMK at physiological pH is 8.7. Antioxidant capacity [1] [2]. AFMK enhances the anti-tumor effect of gemcitabine in PANC-1 cells by regulating the apoptotic pathway.
Related categories
Research Fields>>Cancer
Target point
Human Endogenic Metabolite
In vitro studies have shown that AFMK is one of the metabolites of melatonin, which can be formed through enzymatic or pseudoenzymatic and non enzymatic metabolic pathways. AFMK pretreatment significantly inhibited DNA damage. Through electron spin resonance (ESR) research, AFMK exhibits very high potential for in vitro hydroxyl radical scavenging. The IC50 value obtained from ESR analysis is 338.08 nM. AFMK is a metabolite of melatonin, a poorly studied biogenic amine. Compared with the results obtained by using gemcitabine alone, the combined use of PANC-1 and gemcitabine in AFMK inhibited the production of HSP70 and cIAP-2 [3]. Western Blot analysis [3] Cell line: human pancreatic cancer cell line (PANC-1) Concentration: 0.001,0.1,101000 nM Culture time: Results: The inhibition of HSP70 expression increased from 0.47 (gemcitabine alone) to 0.13 (10 nM AFMK), 0.08 (0.1 nM AFMK) and 0.01 (0.001 nM AFMK).
In vivo research shows that AFMK is an effective antioxidant in the body. AFMK can significantly reverse the radiation induced decrease in total antioxidant capacity of mouse plasma [2]. Animal model: 8-week-old male C57BL mice [2] Dose: 10mg/kg body weight Administration: intraperitoneal injection Results: Mice pretreated with AFMK can significantly reverse the radiation induced decrease in plasma total antioxidant capacity. The comet tail length and tail DNA percentage in the AFMK pre-treatment irradiation group were significantly reduced.